ScaleUp Bio, Singapore’s first and largest precision fermentation contract development and manufacturing organisation (CDMO), has announced that Fusionopolis Ventures, a subsidiary of Economic Development Innovations Singapore, will join ADM as a shareholder. This move is set to bolster ScaleUp Bio’s growth as a leading biomanufacturing platform in Asia, focusing on high-value bio-based speciality molecules across various sectors, including cosmetics, pharmaceuticals, and food.
The partnership aims to enhance ScaleUp Bio’s capabilities by leveraging its commercial pilot facility, operated jointly with A*STAR Singapore Institute of Food and Biotechnology Innovation, and its industrial base in Tuas. This integrated approach is designed to streamline the process from development to commercial production, addressing a critical infrastructure gap for companies needing high-quality fermentation capacity.
Philip Yeo, Chairman of EDIS, expressed confidence in the investment, stating, “This investment reflects our conviction in platforms that combine deep technical capability with disciplined scale-up execution.” He highlighted Singapore’s potential as a strategic launchpad for biomanufacturing, akin to its role in the biopharmaceutical sector.
Fabiana Bianchi, President of Asia-Pacific at ADM, noted the potential of precision fermentation to open new opportunities for producing bio-based ingredients efficiently. The fresh capital and strategic backing are expected to enhance ScaleUp Bio’s ability to serve its customers, reduce execution complexity, and accelerate timelines, positioning it as a key player in the growing biomanufacturing needs of Asia and beyond.
